1973-03 1979-02 서울대학교 의과대학 의학과 대졸(의대) 1981-03 1983-02 서울대학교 의과대학 의학과 대학원졸(석사) 1989-09 1991-08 고려대학교 의과대학교 의학과 대학원졸(박사)
경력
1979-03 1980-02 서울대학교병원 인턴 1980-03 1983-02 서울대학교병원 레지던트 1986-04 1987-02 차병원 과장 1987-04 2000-09 원자력병원 산부인과 과장 1997-07 1997-07 Washington Cancer Institute, USA Visiting doctor 1997-08 1997-08 Mainz University, Germany Visiting doctor 2000-10 2009-01 국립암센터 자궁암센터 센터장 2000-10 현재 국립암센터 자궁암센터 전문의 2001-05 2007-11 국립암센터 자궁암연구과 과장, 책임연구원 2003-04 2007-04 국립암센터 호발암연구과 부장 2007-04 2007-11 국립암센터 이행성임상연구부 부장 2007-06 2012-01 국립암센터 자궁암연구과 수석연구원 2007-12 2009-12 국립암센터 자궁암연구과 과장, 수석연구원 2011-08 2014-08 국립암센터 자궁암센터 센터장 2012-01 2017-02 국립암센터 부인암연구과 수석연구원 2017-03 2018-06 국립암센터 호발암연구과 수석연구원 2019-07 현재 국립암센터 자궁난소암센터 초빙의
논문
2025 SCI-E Neoadjuvant Chemotherapy with Dual Immune Checkpoint Inhibitors for Advanced-Stage Ovarian Cancer: Final Analysis of TRU-D Phase II Nonrandomized Clinical Trial: CLINICAL CANCER RESEARCH. :~ (10.4) 2025 SCI-E PALB2 germline pathogenic variants: frequency, clinical features, and functional analysis of c.3350+5G>A variant in 3987 Korean cancer patients: ESMO OPEN. 10(3):104132~ (7.1) 2025 SCI-E The association between location of BRCA mutation and efficacy of PARP Inhibitor as a frontline maintenance therapy in advanced epithelial ovarian cancer: CANCERS. 17(5):756~ (4.5) 2025 SCI-E A randomized, multicenter, open-label phase III trial of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in platinum-resistant recurrent ovarian cancer: a rationale and study design of the KOV-HIPEC-02 trial: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 35(4):101630~ (4.5) 2024 SCI-E Docetaxel/cisplatin chemotherapy followed by pelvic radiation therapy in patients with high-risk endometrial cancer after staging surgery: a phase II study: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. :~ (6.4) 2024 SCI-E The Efficacy and Safety of Folate Receptor α-Targeted Antibody-Drug Conjugate Therapy in Patients With High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers: A Systematic Review and Meta-Analysis: CANCER MEDICINE. 13(21):e70392~ (2.9) 2024 SCI-E Time-Trend Analysis and Risk Factors for Niraparib-Induced Nausea and Vomiting in Ovarian Cancer: A Prospective Study: CANCER RESEARCH AND TREATMENT. :~ (4.1) 2024 SCI-E The discrepancy of somatic BRCA1/2 pathogenic variants from two different platforms in epithelial ovarian, fallopian tube, and peritoneal cancer: SCIENTIFIC REPORTS. 14:25879~ (3.8) 2024 SCI-E Comparison of survival outcomes and safety between early and late initiation of niraparib maintenance in newly diagnosed advanced epithelial ovarian cancer: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. :~ (4.5) 2024 SCI-E Case report: Extraskeletal Ewing sarcoma with a germline pathogenic variant of SMARCA4: FRONTIERS IN ONCOLOGY. 14:~ (3.5) 2024 SCI-E Left Hemi-Hepatectomy to Resect Metastatic Tumor of Round Ligament of Liver in Patients with Ovarian Cancer: CANCERS. 16(17):3036~ (4.5) 2024 SCI-E The pathologic and clinical outcomes of risk-reducing salpingo-oophorectomy in asymptomatic carriers of homologous recombination repair gene mutation: Journal of Gynecologic Oncology. 36:e15~ (3.4)